Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma

Camptothecin (CPT), a potent inhibitor of topoisomerase I and HIF-1α, failed to demonstrate utility as an anti-cancer agent in early clinical trial investigations, primarily due to limited clinical activity and significant toxicity attributable to unfavorable physicochemical properties (e.g. low pla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Pharm Biomed Anal
Autors principals: Schmidt, Keith T., Peer, Cody J., Huitema, Alwin D. R., Williams, Monique D., Wroblewski, Susan, Schellens, Jan H. M., Madan, Ravi A., Figg, William D.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7068816/
https://ncbi.nlm.nih.gov/pubmed/31927166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpba.2019.113073
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars